Drug Trial Radar · NCT07722767
A Phase 1b Study of CLN-049 in Combination With Azacitidine and Venetoclax in AML Patients
Last checked: Nov 19, 2026Latest source record: Oct 28, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Not yet recruiting
Enrollment
90
Planned (sponsor's estimate)
Start
Oct 15, 2026
Primary completion
Sep 30, 2027
Study completion Aug 31, 2030
Sponsor
- Lead sponsor
- Cullinan Therapeutics Inc.Industry
- Sponsor type
- Industry
- First posted
- Jul 23, 2026
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Non randomized
- Model
- Sequential
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
A Phase 1b, open-label, multicenter, dose escalation and dose expansion study to evaluate the safety, tolerability, pharmacokinetics (PK), and pharmacodynamics (PD) of intravenously (IV) administered CLN-049 in combination with azacitidine (Aza) and venetoclax (Ven) in patients with newly diagnosed (ND) AML.
Conditions
- AML (Acute Myeloid Leukemia)
Interventions
CLN-049Drug
CLN-049 will be initiated using two step-up doses (SUDs), followed by the first target dose (TD) one week later, and weekly thereafter.
AzacitidineDrug
Azacitidine 75 mg/m2 will initially be administered sub-cutaneous or intravenous on days 1 through 7 of a 28-day cycle
VenetoclaxDrug
Venetoclax will initially be administered orally on days 1 through 28 of a 28-day cycle and then reduced to days 1 through 14 in consolidation cycles.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Incidence and severity of adverse events (AEs)/adverse events of special interest (AESIs)/serious adverse events (SAEs) [safety and tolerability] of CLN-049 combined with azacitidine and venetoclaxTime frame: 48 weeks
- Determine recommended dose/schedule of CLN-049 in combination with azacitidine and venetoclaxTime frame: 48 weeks
Locations
5 sites in 1 country. Site status is shown where the registry gives one.
City of Hope
Duarte, California
University of Miami Health System
Miami, Florida
Emory University Hospital
Atlanta, Georgia
New York University Langone Health
New York, New York
MD Anderson
Houston, Texas
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.